The Use of Sildenafil to Treat Pulmonary Hypertension Associated With Interstitial Lung Disease

Respirology. 2010 Nov;15(8):1226-32. doi: 10.1111/j.1440-1843.2010.01860.x.

Abstract

Background and objective: Limited data suggest a benefit following sildenafil treatment in patients with pulmonary hypertension (PH) and interstitial lung disease (ILD). The role of sildenafil in the management of PH in ILD is not clear. We report our experience of ILD patients with PH after 6-month sildenafil therapy.

Methods: We reviewed 15 patients (mean age 55 ± 15 years; 8 men) with ILD (mean FVC 52.6 ± 15.4%) and PH (mean right ventricular systolic pressure 73.8 ± 17.8 mm Hg). Median brain natriuretic peptide: 37 (5-452) pmol/L; mean 6MWD: 156 ± 101 m.

Results: Following 6-month treatment with sildenafil, brain natriuretic peptide levels were lower (n = 12, P = 0.03), 6MWD was higher (n = 6, P < 0.05), but no change in right ventricular systolic pressure (n = 11) was demonstrated.

Conclusions: Our observations suggest that sildenafil may be useful in the management of PH in ILD. Controlled trials are warranted before therapeutic recommendations can be made.

MeSH terms

  • Cohort Studies
  • Exercise Test / drug effects
  • Female
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / etiology
  • Lung Diseases, Interstitial / complications*
  • Male
  • Middle Aged
  • Natriuretic Peptide, Brain / blood
  • Piperazines / therapeutic use*
  • Purines / therapeutic use
  • Sildenafil Citrate
  • Sulfones / therapeutic use*
  • Treatment Outcome
  • Vasodilator Agents / therapeutic use*
  • Walking

Substances

  • Piperazines
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Natriuretic Peptide, Brain
  • Sildenafil Citrate